Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ThermaFix is a non-specific trade name primarily associated with two distinct product categories: medical immobilization devices used in radiation oncology and thermogenic dietary supplements marketed for weight loss. In the clinical setting, ThermaFix (manufactured by Bionix) refers to a thermoplastic immobilization system designed to maintain precise and reproducible patient positioning during radiotherapy, thereby ensuring accurate dose delivery to target tissues while minimizing exposure to healthy anatomy. In the consumer health market, ThermaFix is a brand name for various multi-ingredient dietary supplements. These formulations typically function as thermogenic agents, utilizing a blend of ingredients such as caffeine, green tea extract (rich in epigallocatechin gallate), and capsaicin. The pharmacological mechanism of these supplements involves the stimulation of the sympathetic nervous system, antagonism of adenosine receptors, and inhibition of phosphodiesterase, which collectively promote lipolysis and increase basal metabolic rate. ThermaFix is not an FDA-approved pharmaceutical drug for the treatment of any primary clinical indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ThermaFix.